Skip to main content

Find Clinical Trials

Clinical trial condition

RCC

Explore clinical trials studying RCC. Study availability and eligibility vary by location and protocol.

13 public trials 5 recruiting studies

Refine in advanced search Browse all conditions

RCC trial results

Recruiting

Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma

NCT07300241

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +23 more
Locations: NEO-811 Los Angeles Site Duarte, California, United States

NEO-811 San Diego Site San Diego, California, United States

NEO-811 Connecticut Site New Haven, Connecticut, United States

NEO-811 Chicago Site Zion, Illinois, United States

View Trial Details

Recruiting

Renal Cancer Monitoring Based on ctDNA Methylomics: A Prospective Cohort Study (MEMORY Study)

NCT05917106

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +16 more
Locations: Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China Nanjing, Jiangsu, China

View Trial Details

Recruiting

Sequential Treatment of Cabozantinib for Advanced Renal Cell Carcinoma (RCC)

NCT05931393

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +15 more
Locations: UT Southwestern Medical Center Dallas, Texas, United States

View Trial Details

Recruiting

A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

NCT06682793

Conditions: Adenocarcinoma, Breast Diseases, Breast Neoplasms, +57 more
Locations: Banner MD Anderson Cancer Center Gilbert, Arizona, United States

UCSD Moores Cancer Center La Jolla, California, United States

UCLA Medical Center Los Angeles, California, United States

Mayo Clinic Jacksonville, Florida, United States

View Trial Details

Recruiting

A Study of SPX-303, a Bispecific Antibody Targeting LILRB2 and PD-L1 in Patients With Solid Tumors

NCT06259552

Conditions: CRC, Carcinoma, Carcinoma, Squamous Cell, +9 more
Locations: Mayo Clinic Arizona Phoenix, Arizona, United States

HonorHealth Research and Innovation Institute Scottsdale, Arizona, United States

Mayo Clinic Florida Jacksonville, Florida, United States

Mayo Clinic Rochester Rochester, Minnesota, United States

View Trial Details

Not Yet Recruiting

A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.

NCT07689812

Conditions: Adenocarcinoma, Advanced Solid Tumors, Advanced Solid Tumors Cancer, +54 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

A Multicenter Real-World Study on TKI Therapy After Progression on First-Line TKI/IO Therapy or TKI/IO Therapy After Progression on First-Line TKI in Chinese Patients With Metastatic Renal Cell Carcinoma (mRCC)

NCT07324876

Conditions: RCC
Locations: Tianjin Medical University Cancer Institute and Hospital Tianjin, China

View Trial Details

Not Yet Recruiting

A Prospective Registry Study of Stereotactic Ablative Radiotherapy (SABR) for Oligometastatic/Oligometastatic Renal Cell Carcinoma

NCT06585878

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +16 more
Locations: Not specified

View Trial Details

Not Yet Recruiting

Vorolanib Combined With Cadonilimab in the Treatment of Untreated Advanced RCC Patients

NCT06577961

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +16 more
Locations: Not specified

View Trial Details

Completed

Nivolumab in mRCC Patients: Treg Function, T-cell Access and NK Interactions to Predict and Improve Efficacy

NCT03891485

Conditions: Adenocarcinoma, Carcinoma, Carcinoma, Renal Cell, +15 more
Locations: IRCCS Istituto Nazionale Tumori di Napoli Naples, Italy

View Trial Details